Interferon Alfa-N3

CHEMBL2109047 Phase 4 Approuvé Protein

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

— g/mol

LogP

—

Phase

4

This naturally derived human interferon alfa is used as an intralesional injection to treat refractory genital warts (condyloma acuminata). It works by stimulating local immune responses to clear the human papillomavirus (HPV)-infected cells. It is used when other treatments have failed.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

HBD / HBA

- / -

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Foire aux questions

This naturally derived human interferon alfa is used as an intralesional injection to treat refractory genital warts (condyloma acuminata). It works by stimulating local immune responses to clear the human papillomavirus (HPV)-infected cells. It is used when other treatments have failed.

Yes, Interferon Alfa-N3 is an approved drug. It has reached clinical phase 4. It is classified as a Protein.

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL2109047. Open-access bioactivity database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-02-27.

PillFYI

Vous cherchez des informations accessibles aux patients ?

Interferon Alfa-N3 sur PillFYI

Données Clés

Synonymes: 1

Liens externes

ChEMBL CHEMBL2109047

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Avertissement médical

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.